| How does cancer develop in Barrett's esophagus? |
|
Barrett MT, Galipeau PC, Sanchez CA, Emond MJ, Reid BJ. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene 1996; 12(9):1873-8. |
|
Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996; 13(9):1867-73. |
|
Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett oesophagus. Nature Genetics 1999; 22(1):106-9. |
|
Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Research 1994; 54(9):2292-5. |
|
Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN, Walker SJ, Sutton R, Meltzer SJ, Field JK. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998; 78(7):950-7. |
|
Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, Garewal HS. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989; 97(4):815-20. |
|
Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proceedings of the National Academy of Sciences of the United States of America 1996; 93(14):7081-4. |
|
Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Research 1995; 55(15):3406-11. |
|
Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994; 107(4):1012-8. |
|
Hammoud ZT, Kaleem Z, Cooper JD, Sundaresan RS, Patterson GA, Goodfellow PJ. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996; 56(19):4499-502. |
|
Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266(5192):1821-8. |
|
Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246(4930):629-34. |
|
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ, Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71(4):587-97. |
|
Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998; 115(6):1381-6. |
|
Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10(9):1054-72. |
|
Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clinic Proceedings 2001; 76(4):438-46. |
|
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70(6):923-35. |
|
Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Research 1991; 51(12):3075-9. |
|
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362(6423):847-9. |
|
Muzeau F, Flejou JF, Thomas G, Hamelin R. Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers. Int J Cancer 1997; 72(1):27-30. |
|
Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid BJ. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994; 106(6):1589-95. |
|
Neshat K, Sanchez CA, Galipeau PC, Cowan DS, Ramel S, Levine DS, Reid BJ. Barrett's esophagus: a model of human neoplastic progression. Cold Spring Harbor Symposia on Quantitative Biology 1994; 59:577-83 |
|
Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194(4260):23-8. |
|
Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Research 1999; 59(19):4784-7. |
|
Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE. Progression to cancer in Barrett's esophagus is associated with genomic instability. Laboratory Investigation 1989; 60(1):65-71. |
|
Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93(1):1-11. |
|
Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. American Journal of Gastroenterology 2000; 95(7):1669-76. |
|
Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. The American Journal of Gastroenterology 2001; 96(10):2839-48. |
|
Reid BJ. p53 and neoplastic progression in Barrett's esophagus. The American Journal of Gastroenterology 2001; 96(5):1321-3. |
|
Robaszkiewicz M, Hardy E, Volant A, Nousbaum JB, Cauvin JM, Calament G, Robert FX, Saleun JP, Gouerou H. [Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases]. Gastroenterol Clin Biol 1991; 15(10):703-10. |
|
Tarmin L, Yin J, Zhou X, Suzuki H, Jiang HY, Rhyu MG, Abraham JM, Krasna MJ, Cottrell J, Meltzer SJ. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. Cancer Res 1994; 54(23):6094-6. |
|
Teodori L, Gohde W, Persiani M, Ferrario F, Tirindelli Danesi D, Scarpignato C, Di Tondo U, Alo P, Capurso L. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998; 34(6):257-63. |
|
Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Research 1997; 57(13):2619-22. |
|
Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Research 2001; 61(22):8284-9. |
|
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70(6):937-48. |
|
